710 related articles for article (PubMed ID: 32512289)
1. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
Jacobs JJL
Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
[TBL] [Abstract][Full Text] [Related]
2. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
3. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
7. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Case JB; Rothlauf PW; Chen RE; Kafai NM; Fox JM; Smith BK; Shrihari S; McCune BT; Harvey IB; Keeler SP; Bloyet LM; Zhao H; Ma M; Adams LJ; Winkler ES; Holtzman MJ; Fremont DH; Whelan SPJ; Diamond MS
Cell Host Microbe; 2020 Sep; 28(3):465-474.e4. PubMed ID: 32798445
[TBL] [Abstract][Full Text] [Related]
8. Why do children seem to be more protected against COVID-19? A hypothesis.
Sposato B; Scalese M
Med Hypotheses; 2020 Oct; 143():110151. PubMed ID: 32763661
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
[TBL] [Abstract][Full Text] [Related]
10. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
[TBL] [Abstract][Full Text] [Related]
11. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
12. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
[TBL] [Abstract][Full Text] [Related]
13. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
14. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
Khalaj-Hedayati A
J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833
[TBL] [Abstract][Full Text] [Related]
15. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
16. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Konwarh R
Front Immunol; 2020; 11():1531. PubMed ID: 32655584
[No Abstract] [Full Text] [Related]
18. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
[TBL] [Abstract][Full Text] [Related]
19. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
20. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
Galili U
Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
